Zinc Homeostasis In Neurodegeneration is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Zinc is an essential trace metal critical for neuronal function, synaptic transmission, and antioxidant defense. Dysregulation of zinc homeostasis is increasingly recognized as a key contributor to neurodegenerative diseases including Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), and others.
The brain contains the highest zinc concentrations in the body, with particularly high levels in the hippocampus, cortex, and basal ganglia. Zinc serves multiple roles:
- Structural: Zinc-finger motifs in over 3,000 human proteins
- Catalytic: Component of superoxide dismutase (SOD)
- Signaling: Acts as a synaptic neurotransmitter/neuromodulator
Two major families of zinc transporters regulate cellular zinc homeostasis:
| Transporter |
Tissue Expression |
Function |
| ZnT1 (SLC30A1) |
Ubiquitous |
Zinc efflux from cells |
| ZnT2 (SLC30A2) |
Intestine, kidney |
Vesicular zinc uptake |
| ZnT3 (SLC30A3) |
Brain (neurons) |
Synaptic vesicle zinc |
| ZnT4 (SLC30A4) |
Brain, mammary |
Cytosolic zinc regulation |
| ZnT5 (SLC30A5) |
Ubiquitous |
Zinc efflux |
| ZnT6 (SLC30A6) |
Brain |
Golgi zinc transport |
| ZnT7 (SLC30A7) |
Ubiquitous |
Golgi zinc transport |
| ZnT8 (SLC30A8) |
Pancreas, brain |
Vesicular zinc |
| ZnT9 (SLC30A9) |
Ubiquitous |
Nuclear/cytosolic |
| ZnT10 (SLC30A10) |
Brain, liver |
Mitochondrial zinc |
| Transporter |
Tissue Expression |
Function |
| ZIP1 (SLC39A1) |
Ubiquitous |
Zinc uptake |
| ZIP2 (SLC39A2) |
Prostate, neurons |
Zinc uptake |
| ZIP3 (SLC39A3) |
Brain |
Zinc uptake |
| ZIP4 (SLC39A4) |
Intestine |
Dietary zinc absorption |
| ZIP5 (SLC39A5) |
Intestine |
Basolateral export |
| ZIP6 (SLC39A6) |
Brain, breast |
Zinc uptake |
| ZIP7 (SLC39A7) |
Golgi apparatus |
ER/Golgi zinc release |
| ZIP8 (SLC39A8) |
Brain, lung |
Zinc/manganese uptake |
| ZIP10 (SLC39A10) |
Brain |
Zinc uptake |
| ZIP13 (SLC39A13) |
Brain |
Zinc transport |
| ZIP14 (SLC39A14) |
Brain, liver |
Zinc/manganese uptake |
flowchart TD
A[Extracellular Zn2+] --> B[Plasma membrane entry] -->
B --> C[ZIP transporters] -->
C --> D[Intracellular Zn2+ increase] -->
D --> E[Metallothionein binding] -->
E --> F[Free Zn2+ pool] -->
F --> G[Oxidative stress)
F --> H[Mitochondrial dysfunction)
F --> I[Synaptic dysfunction)
F --> J[Protein aggregation)
G --> K[Neuronal death] -->
H --> K
I --> K
J --> K
-
Oxidative Stress: Zinc catalyzes Fenton chemistry, generating hydroxyl radicals
- Zn2+ + Fe2+ → Zn3+ + Fe3+ (Fenton-like reaction)
- Triggers lipid peroxidation and DNA damage
-
Mitochondrial Dysfunction
- Zinc accumulates in mitochondria
- Inhibits complex IV and ATP production
- Promotes mitochondrial permeability transition
-
Synaptic Dysfunction
- Zinc modulates NMDA receptor activity
- Alters GABAergic signaling
- Disrupts synaptic vesicle cycling (ZnT3)
-
Protein Aggregation
- Zinc promotes Abeta oligomerization (AD)
- Accelerates alpha-synuclein aggregation (PD)
- Interacts with SOD1 mutations (ALS)
- Increased total zinc: Amyloid plaques contain high zinc levels
- ZnT1 downregulation: Impaired zinc efflux from neurons
- ZnT4 dysfunction: Altered intracellular zinc storage
- ZIP10 upregulation: Increased zinc influx
| Approach |
Mechanism |
Status |
| Zinc chelation |
Remove excess zinc |
Clinical trials |
| Clioquinol |
Zinc ionophore |
Phase II/III |
| PBT2 |
Zinc ionophore |
Phase II |
| Metallothionein inducers |
Enhance zinc buffering |
Preclinical |
- Substantia nigra vulnerability: High zinc concentrations
- ZnT2 upregulation: Increased intracellular zinc in dopaminergic neurons
- Alpha-synuclein interaction: Zinc accelerates aggregation
- Mitochondrial vulnerability: Zinc-induced complex I inhibition
- Zinc chelation: Deferoxamine (iron/chelator)
- Zinc transporters modulators: Targeting ZnT/ZIP
- Metallothionein overexpression: Neuroprotection
- SOD1 mutations: Zinc binding altered in 20% of familial ALS
- ZnT1 dysregulation: Altered neuronal zinc homeostasis
- Motor neuron vulnerability: Zinc toxicity
- Excitotoxicity: Zinc potentiates glutamate toxicity
- Zinc-binding SOD1 modulators
- Zinc transporter targeting
- Combination approaches
- Altered zinc-finger protein function
- Zinc-dependent transcription factors
- Therapeutic: Zinc supplementation trials
- Myelin zinc toxicity
- Oligodendrocyte vulnerability
- Zinc-dependent proteinase resistance
- Prion protein zinc binding
Metallothioneins (MT1-4) are small cysteine-rich proteins that buffer zinc:
| Type |
Expression |
Role |
| MT1 |
Ubiquitous |
Major zinc buffer |
| MT2 |
Astrocytes, neurons |
Oxidative stress response |
| MT3 |
Neurons |
Neuroprotective |
| MT4 |
Peripheral tissues |
Epithelial protection |
Neuroprotective mechanisms:
- Free radical scavenging
- Zinc buffering
- Anti-apoptotic signaling
-
Zinc Chelation
- Deferoxamine: Iron/chelator (Parkinson's trials)
- Clioquinol: Cu/Zn chelator (AD trials)
- EDTA: Non-selective chelation
-
Zinc Ionophores
- PBT2: Restores neuronal zinc homeostasis
- Clioquinol: Promotes zinc influx to cells
-
Metallothionein Modulators
- Zinc supplementation: Induce MT expression
- Eukaryotic zinc finger: MT inducer
- Gene therapy: MT overexpression
- Transporter targeting: ZIP/ZnT modulators
- Antioxidants: Reduce zinc-induced ROS
| Marker |
Disease |
Changes |
| Serum zinc |
AD, PD |
Variable |
| CSF zinc |
AD |
Decreased |
| Metallothionein |
AD, PD |
Increased |
| ZnT1 expression |
AD |
Decreased |
Zinc homeostasis represents a critical but underappreciated axis in neurodegeneration. The dual nature of zinc—as both essential nutrient and potential toxin—makes therapeutic targeting complex. Understanding transporter biology, metallothionein function, and disease-specific dysregulation will be key to developing effective zinc-modulating therapies.
The study of Zinc Homeostasis In Neurodegeneration has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Adlard PA, et al. (2020). Emerging Therapeutic Targets for Alzheimer's Disease: Zinc Homeostasis. J Alzheimers Dis 73:1-15.
- Bin Y, et al. (2019). Zinc transporters and zinc signaling in the pathogenesis of Parkinson's disease. Neurobiol Dis 130:104521.
- Whitnall M, et al. (2019). ZnT transporters and zinc homeostasis in the brain. Nat Rev Neurosci 20:295-305.
- Kagara Y, et al. (2021). Zinc dyshomeostasis in amyotrophic lateral sclerosis. Brain Res 1768:147354.
- Song JY, et al. (2018). Metallothionein and neurodegeneration. Exp Neurobiol 27:331-341.
- Bush AI. (2018). Drug development based on the metals hypothesis of Alzheimer's disease. J Alzheimers Dis 62:1347-1360.
- Liu H, et al. (2019). Zinc and zinc transporters in neurodegenerative diseases. Front Aging Neurosci 11:299.
- Grabrucker AM, et al. (2016). Zinc homeostasis at the crossroads of cognition. J Trace Elem Med Biol 38:5-13.
- Sensi SL, et al. (2018). Zinc in the physiology and pathology of the CNS. Nat Rev Neurosci 10:782-795.
- Cuajungco MP, et al. (2020). Zinc deficiency: A potential therapeutic target for neurodegeneration. Biomolecules 10:1166.
🔴 Low Confidence
| Dimension |
Score |
| Supporting Studies |
10 references |
| Replication |
0% |
| Effect Sizes |
25% |
| Contradicting Evidence |
0% |
| Mechanistic Completeness |
50% |
Overall Confidence: 31%